InvestorsHub Logo
Followers 0
Posts 42
Boards Moderated 0
Alias Born 07/23/2013

Re: None

Wednesday, 02/10/2016 9:44:37 AM

Wednesday, February 10, 2016 9:44:37 AM

Post# of 12450
With all the new hires they must be confident of signing new license deals soon. Rising royalty income from Fofivo is great but they may not earn any milestone payments in 2016 from Edgemont. Therefore they should earn up front license fees from Rizaport ( US and Europe ) and Tadalafil. Without these their Forfivo royalty income will be 1.7m to 2.0m at best. This is not enough to cover costs. The other potential source is the Par Opoid drug. It should get approval this year and if they win the paragraph iv litigation they may be entitled to a payment from Par. Does anybody have a view on this. Maybe they are not due any payment on approval from Par as they have paid all the costs.
Anyway IGXT should have three drugs selling next year forfivo, rizaport and the suboxone drug.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IGXT News